Publications

Add filters (0)

898 results

Prognostic Performance of Phosphatidylethanol With Noninvasive Liver Fibrosis Tests in Alcohol-Related Liver Disease.

April 1, 2026

Gastroenterology

Abstract BACKGROUND & AIMS Alcohol is a key driver of liver-related mortality, and phosphatidylethanol (PEth) is a direct biomarker of alcohol intake. We investigated the prognostic performance of PEth with noninvasive liver fibrosis tests (NITs) for predicting hepatic decompensation in an alcohol-related liver disease (ALD) at-risk population. METHODS Prospective cohort study with 411 at risk […]

Read publication

A meta-analysis of smoking and fracture risk to update the FRAX® tool.

April 1, 2026

Osteoporos Int

Abstract UNLABELLED In this meta-analysis of international cohorts, current smoking is confirmed as a significant BMD-independent predictor of future fracture with a stronger relationship in men than in women. A causative and reversible effect of smoking on fracture risk is suggested by past smoking having a significantly lower risk than current smoking. PURPOSE In this […]

Read publication

A Novel Fibroblast Activation Protein-Based Algorithm to Assess Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.

April 1, 2026

J Gastroenterol Hepatol

Abstract BACKGROUND Noninvasive fibrosis testing is crucial for metabolic dysfunction-associated steatotic liver disease (MASLD) management. This study evaluated a marker of activated mesenchymal fibrogenic cells, circulating fibroblast activation protein (cFAP), in a novel diagnostic algorithm, FAP Index, for patients with MASLD. METHODS Two retrospective cohorts recruited from tertiary hepatology clinics were studied as training (n = 160) […]

Read publication

Differential Effects of Antifibrotic Treatment on Outcome Prediction via Serial Matrix Metalloproteinase-Degraded C-Reactive Protein Neoepitope Levels in Idiopathic Pulmonary Fibrosis.

April 1, 2026

Chest

Abstract BACKGROUND Idiopathic pulmonary fibrosis (IPF) is characterized by an increase in proteolytic enzymes, including matrix metalloproteinases that degrade the extracellular matrix and markers of localized inflammation. Protein fragments (neoepitopes) are detectable in the circulation. RESEARCH QUESTION Can short-term trajectories of neoepitopes after initiation of antifibrotic treatment predict therapy-related outcomes, including mortality, in patients with […]

Read publication

Collagen protein supplementation does not modulate biomarkers of bone metabolism following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.

March 27, 2026

Clin Nutr ESPEN

Abstract BACKGROUND & AIMS Healing after total hip arthroplasty (THA) involves remodelling of collagenous tissues, such as bone. While collagen protein supplementation has been suggested to modulate bone metabolism, the effects following THA are yet to be investigated. Therefore, we aimed to characterize changes in biomarkers of bone metabolism following THA and to assess the […]

Read publication

Characterization of a novel assay for full-length endotrophin in heart failure with preserved ejection fraction.

March 18, 2026

Sci Rep

Abstract UNLABELLED Endotrophin is a matrikine released from the C-terminus of the alpha-3 chain of type VI collagen, gaining increasing attention both as a biomarker and as a therapeutic target in the cardiometabolic space. So far, it has been quantified in circulation by the PRO-C6 assay, which detects different-sized proteolytic fragments of the C-terminus, including […]

Read publication

Collagen type I degradation peptide as a predictive biomarker for mortality in ST-elevated myocardial infarction.

March 4, 2026

Clin Res Cardiol

Abstract BACKGROUND AND AIMS Tissue remodelling and extracellular matrix (ECM) changes are primary consequences of ST-elevated myocardial infarction (STEMI), leading to an increased risk of developing heart failure and mortality. Collagen type I is the top constituent of the cardiac ECM and is rapidly degraded at sites of tissue injury occurring in STEMI. We aimed […]

Read publication

Fibrosis activity vs. disease stage: Complementary and independent predictors of outcomes in alcohol-related liver disease.

March 1, 2026

JHEP Rep

Abstract BACKGROUND & AIMS Excessive alcohol consumption accelerates fibrosis progression in steatotic liver disease. Disease activity can be described by fibrogenic activity, of which collagen formation is a central process. Type III collagen formation (PRO-C3) is a biomarker of fibrosis activity. We aimed to evaluate whether PRO-C3 predicts clinical outcomes in alcohol-related liver disease (ALD) […]

Read publication